Literature DB >> 21160571

Present concepts in management of atrial fibrillation: From drug therapy to ablation.

Giovanni B Forleo1, Luca Santini, Francesco Romeo.   

Abstract

Atrial fibrillation (AF) management requires knowledge of its pattern of presentation, underlying conditions, and decisions about restoration and maintenance of sinus rhythm, control of the ventricular rate, and anti-thrombotic therapy. Maintenance of sinus rhythm is a desirable goal in AF patients because the prevention of recurrence may improve cardiac function, relieve symptoms and reduce the likelihood of adverse events. Anti-arrhythmic drug therapy is the first-line treatment for patients with paroxysmal and persistent AF based on current guidelines. However, currently used drugs have limited efficacy and cause cardiac and extracardiac toxicity. Thus, there is a continued need to develop new drugs, device and ablative approaches to rhythm management. Additionally, simpler and safer stroke prevention regimens are needed for AF patients on life-long anticoagulation, including occlusion of the left atrial appendage. The results of the Randomized Evaluation of Long-Term Anticoagulant Therapy study are encouraging in these settings. Knowledge on the pathophysiology of AF is rapidly expanding and identification of focally localized triggers has led to the development of new treatment options for this arrhythmia. Conversely, the clinical decision whether to restore and maintain sinus rhythm or simply control the ventricular rate has remained a matter of intense debate. In the minority of patients in whom AF cannot be adequately managed by pharmacological therapy, the most appropriate type of non-pharmacological therapy must be selected on an individualized basis. Curative treatment of AF with catheter ablation is now a legitimate option for a large number of patients. The evolution of hybrid therapy, in which two or more different strategies are employed in the same patient, may be an effective approach to management of AF. In any case, planning a treatment regimen for AF should include evaluation of the risks inherent in the use of various drugs as well as more invasive strategies.

Entities:  

Keywords:  Antiarrhythmic medications; Atrial fibrillation; Catheter ablation

Year:  2009        PMID: 21160571      PMCID: PMC2998799          DOI: 10.4330/wjc.v1.i1.11

Source DB:  PubMed          Journal:  World J Cardiol


  77 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

2.  Obliteration of the left atrial appendage for prevention of thromboembolism.

Authors:  Jonathan L Halperin; Mardi Gomberg-Maitland
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

3.  Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials.

Authors:  Stefan H Ostermayer; Mark Reisman; Paul H Kramer; Ray V Matthews; William A Gray; Peter C Block; Heyder Omran; Antonio L Bartorelli; Paolo Della Bella; Carlo Di Mario; Carlo Pappone; Paul N Casale; Jeffrey W Moses; Athena Poppas; David O Williams; Bernhard Meier; Allan Skanes; Paul S Teirstein; Michael D Lesh; Toshiko Nakai; Yves Bayard; Kai Billinger; Thomas Trepels; Ulrike Krumsdorf; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

4.  Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function.

Authors:  Claudio Tondo; Massimo Mantica; Giovanni Russo; Andrea Avella; Lucia De Luca; Augusto Pappalardo; Rafael Lopes Fagundes; Edo Picchio; Francesco Laurenzi; Vito Piazza; Irma Bisceglia
Journal:  Pacing Clin Electrophysiol       Date:  2006-09       Impact factor: 1.976

5.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

6.  First human experience with pulmonary vein isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation.

Authors:  A Natale; E Pisano; J Shewchik; D Bash; R Fanelli; D Potenza; P Santarelli; R Schweikert; R White; W Saliba; L Kanagaratnam; P Tchou; M Lesh
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

7.  Transthoracic versus transesophageal cardioversion of atrial fibrillation under light sedation: a prospective randomized trial.

Authors:  Luca Santini; Mark M Gallagher; Lida P Papavasileiou; Valentina Romano; Alessia Topa; Luciano Di Battista; Maurizio Aracri; Francesco Romeo
Journal:  Pacing Clin Electrophysiol       Date:  2007-12       Impact factor: 1.976

Review 8.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

Review 9.  Advances in the surgical treatment of atrial fibrillation.

Authors:  A Marc Gillinov; Patrick M McCarthy
Journal:  Cardiol Clin       Date:  2004-02       Impact factor: 2.213

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  4 in total

1.  International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation.

Authors:  Jorge Suarez; Jonathan P Piccini; Li Liang; John J Atherton; Christopher S Hayward; Henry Krum; Gregg C Fonarow; Renato D Lopes; Adrian F Hernandez
Journal:  Am Heart J       Date:  2012-03-27       Impact factor: 4.749

2.  Atrial flutter in a patient with glioblastoma multiforme: problems in treating thromboembolic complications.

Authors:  Alexander Liu; Pawan Pusalkar
Journal:  BMJ Case Rep       Date:  2011-06-29

3.  Pharmacological management of atrial fibrillation: one, none, one hundred thousand.

Authors:  Fabiana Lucà; Mark La Meir; Carmelo Massimiliano Rao; Orlando Parise; Ludovico Vasquez; Rocco Carella; Roberto Lorusso; Benedetto Daniela; Jos Maessen; Gian Franco Gensini; Sandro Gelsomino
Journal:  Cardiol Res Pract       Date:  2011-04-26       Impact factor: 1.866

4.  Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey.

Authors:  C Narasimhan; Jagmohan Singh Verma; A G Ravi Kishore; Balbir Singh; Sameer Dani; Kamaldeep Chawala; Azizul Haque; Aftab Khan; Mohan Nair; Amit Vora; V Rajasekhar; Joy M Thomas; Anoop Gupta; Ajay Naik; V S Prakash; Lisa Naditch; P Gabriel Steg
Journal:  Indian Heart J       Date:  2016-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.